Moderna, Inc. (NASDAQ:MRNA) today announced that it has received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for a partial change...
mRNA-1283 induced a more robust immune response compared to Spikevax® COVID-19 vaccine, mRNA-1273.222
Next-generation mRNA vaccine design offers the potential of longer shelf life...
The Company's ESG strategy demonstrates its efforts to advance global health and environmental sustainability, as well as its commitments to employees and communities
Moderna,...
Moderna has submitted marketing authorization applications for the investigational RSV vaccine, mRNA-1345, with the European Medicines Agency, Swissmedic, and the Therapeutic Goods Administration...
The Enterprise Solutions Hub in the Philippines will support the Asia Pacific region and complements Moderna's Enterprise Solutions Hubs in Warsaw, Poland, and...
Announcement follows recent authorization of the Company's mRNA COVID-19 vaccine in Argentina, Canada, Israel, the US, and Taiwan for active immunization to prevent...
Moderna, Inc., (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Therapeutic Goods Administration (TGA) in Australia has...
